切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2025, Vol. 14 ›› Issue (02) : 225 -231. doi: 10.3877/cma.j.issn.2095-3232.2025041

临床研究

肝动脉灌注化疗联合仑伐替尼及PD-1抑制剂与肝动脉灌注化疗联合仑伐替尼治疗不可切除肝癌的疗效比较
曾士桃1, 严庆2, 廖珊2, 陈焕伟1,2,()   
  1. 1. 524023 广东省湛江市,广东医科大学第一临床学院
    2. 528010 广东省佛山市第一人民医院肝脏胰腺外科
  • 收稿日期:2024-12-10 出版日期:2025-04-10
  • 通信作者: 陈焕伟
  • 基金资助:
    广东省科学技术奖培育项目(2020001003307)2023年佛山市自筹经费类科技创新项目(2320001006090)

Hepatic arterial infusion chemotherapy(HAIC) combined with lenvatinib plus PD-1 inhibitor versus HAIC combined with lenvatinib for unresectable hepatocellular carcinoma

Shitao Zeng1, Qing Yan2, Shan Liao2, Huanwei Chen1,2,()   

  1. 1. The First Clinical College of Guangdong Medical University,Zhanjiang 524023,China
    2. Department of Hepatobiliary and Pancreatic Surgery,the First People’s Hospital of Foshan,Foshan 528010,China
  • Received:2024-12-10 Published:2025-04-10
  • Corresponding author: Huanwei Chen
引用本文:

曾士桃, 严庆, 廖珊, 陈焕伟. 肝动脉灌注化疗联合仑伐替尼及PD-1抑制剂与肝动脉灌注化疗联合仑伐替尼治疗不可切除肝癌的疗效比较[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 225-231.

Shitao Zeng, Qing Yan, Shan Liao, Huanwei Chen. Hepatic arterial infusion chemotherapy(HAIC) combined with lenvatinib plus PD-1 inhibitor versus HAIC combined with lenvatinib for unresectable hepatocellular carcinoma[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 225-231.

目的

比较肝动脉灌注化疗(HAIC)联合仑伐替尼及PD-1 抑制剂与HAIC 联合仑伐替尼治疗不可切除肝细胞癌(肝癌)的临床疗效及安全性。

方法

回顾性分析2020 年4 月至2023 年12 月在佛山市第一人民医院84 例经病理活检或影像学检查诊断不可切除肝癌患者临床资料。患者均签署知情同意书,符合医学伦理学规定。其中男76 例,女8 例;年龄32~75 岁,中位年龄54 岁。按照治疗方法不同,其中48 例接受HAIC 联合仑伐替尼及PD-1 抑制剂治疗(三联组),36 例接受HAIC 联合仑伐替尼治疗(二联组),HAIC 采用改良的FOLFOX6 方案。比较两组患者无进展生存期(PFS)、总体生存期(OS)、肿瘤客观缓解率(ORR)、疾病控制率(DCR)和治疗相关不良事件。两组率的比较采用χ2 检验或Fisher 确切概率法,生存分析采用Kaplan-Meier 法和Log-rank 检验。

结果

生存分析显示,三联组中位PFS 为10.6 个月,明显优于二联组的5.2 个月(χ2=9.30,P<0.05);而三联组ORR、DCR 分别为70.8%(34/48)、93.8%(45/48),二联组相应为66.7%(24/36)、86.1%(31/36),差异均无统计学意义(χ2=0.167,-;P>0.05);两组不良反应发生率分别为96%(46/48)、89%(32/36),差异亦无统计学意义(P>0.05)。两组各有5 例行转化手术治疗,术后病理检查提示三联组4 例达病理学完全缓解(pCR),二联组1 例达pCR。Cox 多因素回归分析显示,相较于三联治疗,二联治疗方式为PFS 独立危险因素(HR=1.924,95%CI:1.150~3.220,P<0.05)。

结论

HAIC 联合仑伐替尼及PD-1 抑制剂的三联治疗方案在延缓肿瘤进展方面优于HAIC 联合仑伐替尼的二联治疗方案,三联方案可能有更高的肿瘤坏死率。但在ORR、DCR 等方面,两种治疗方案疗效相当。

Objective

To compare clinical efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib plus PD-1 inhibitor and HAIC combined with lenvatinib in the treatment of unresectable hepatocellular carcinoma (HCC).

Methods

Clinical data of 84 patients diagnosed with unresectable HCC by pathological biopsy or imaging examination in the First People’s Hospital of Foshan from April 2020 to December 2023 were analyzed retrospectively.The informed consents of all patients were obtained and the local ethical committee approval was received.Among them,76 patients were male and 8 female, aged from 32 to 75 years, with a median age of 54 years.According to different treatment methods, 48 patients received HAIC combined with lenvatinib plus PD-1 inhibitor(triple group), and 36 cases were treated with HAIC combined with lenvatinib (double group).HAIC was given using modified FOLFOX6 regimen.The progression-free survival (PFS), overall survival (OS),objective remission rate (ORR), disease control rate (DCR) and treatment-related adverse events were compared between two groups.The rate comparison between two groups was conducted by Chi-square test or Fisher’s exact probability test.Survival analysis was performed by Kaplan-Meier method and Log-rank test.

Results

Survival analysis showed that the median PFS in the triple group was 10.6 months, significantly longer than 5.2 months in the double group (χ2=9.30, P<0.05).However, the ORR and DCR in the triple group were 70.8%(34/48) and 93.8%(45/48), and 66.7%(24/36) and 86.1%(31/36) in the double group, with no statistical significance between two groups (χ2=0.167,-; both P>0.05).The incidence of adverse reactions in the triple and double groups were 96%(46/48) and 89%(32/36), with no statistical significance between two groups (P>0.05).5 patients in each group underwent conversion surgery.Postoperative pathological examination indicated that 4 patients in the triple group achieved pathologic complete response (pCR), and 1 patient in the double group achieved pCR.Multivariate Cox regression analysis showed that compared with triple therapy, double therapy was an independent risk factor of PFS (HR=1.924, 95%CI: 1.150-3.220,P<0.05).

Conclusions

The triple therapy of HAIC combined with lenvatinib plus PD-1 inhibitor is superior to HAIC combined with lenvatinib in delaying tumor progression, and triple therapy may yield a higher tumor necrosis rate.However, two regimens are equivalent in terms of ORR and DCR.

表1 两组不可切除肝癌患者一般资料比较
表2 两组患者不可切除肝癌肿瘤疗效评价[例(%)]
图1 两组不可切除肝癌患者Kaplan-Meier 生存曲线比较
表3 不可切除肝癌患者PFS 影响因素Cox 回归分析
表4 不可切除肝癌患者OS 影响因素Cox 回归分析
表5 两组不可切除肝癌患者不良事件比较(例)
[1]
Park JW, Chen M, Colombo M, et al.Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J].Liver Int, 2015, 35(9): 2155-2166.DOI: 10.1111/liv.12818.
[2]
Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2021, 71(3): 209-249.DOI: 10.3322/caac.21660.
[3]
Kokudo N, Takemura N, Hasegawa K, et al.Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017(4th JSH-HCC guidelines) 2019 update[J].Hepatol Res, 2019, 49(10):1109-1113.DOI: 10.1111/hepr.13411.
[4]
中华人民共和国国家卫生健康委员会.原发性肝癌诊疗指南(2022年版)[J].中国实用外科杂志, 2022, 42(3): 241-273.DOI: 10.19538/j.cjps.issn1005-2208.2022.03.01.Bureau of Medical Administration of National Health Commission of the People’s Republic of China.Standardization for diagnosis and treatment of hepatocellular carcinoma(2022 edition)[J].Chin J Pract Surg, 2022, 42(3): 241-273.DOI: 10.19538/j.cjps.issn1005-2208.2022.03.01.
[5]
Mai Q, Mo Z, Shi F, et al.Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma[J].J Clin Oncol, 2020, 38(15_suppl): e16603.DOI:10.1200/jco.2020.38.15_suppl.e16603.
[6]
杨宇光, 唐辉, 谭志明, 等.仑伐替尼、PD-1抑制剂联合肝动脉栓塞灌注化疗治疗不可切除肝癌疗效[J/OL].中华肝脏外科手术学电子杂志, 2023, 12(1): 55-60.DOI: 10.3877/cma.j.issn.2095-3232.2023.01.011.Yang YG, Tang H, Tan ZM, et al.Efficacy of ranvartinib, PD-1 inhibitor combined with hepatic artery embolization and chemotherapy in the treatment of unresectable liver cancer[J/OL].Chin J Hepatic Surg (Electronic Edition), 2023, 12(1): 55-60.DOI: 10.3877/cma.j.issn.2095-3232.2023.01.011.
[7]
梁雄, 伍楚蓉, 唐武兵, 等.介入治疗联合仑伐替尼及信迪利单抗治疗中晚期肝癌的近期疗效观察[J].现代肿瘤医学, 2023, 31(20):3812-3817.Liang X, Wu CR, Tang WB, et al.Short-term efficacy of interventional therapy combined with Lenvatinib and Sintlimab in the treatment of advanced hepatocellular carcinoma[J].J Mod Oncol, 2023, 31(20):3812-3817.
[8]
Lencioni R, Llovet JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J].Semin Liver Dis, 2010, 30(1): 52-60.DOI: 10.1055/s-0030-1247132.
[9]
Zeng H, Zheng R, Guo Y, et al.Cancer survival in China, 2003-2005:a population-based study[J].Int J Cancer, 2015, 136(8): 1921-1930.DOI: 10.1002/ijc.29227.
[10]
何传超, 肖治宇.晚期肝癌综合治疗模式与策略[J/OL].中华肝脏外科手术学电子杂志, 2023, 12(5): 486-489.DOI: 10.3877/cma.j.issn.2095-3232.2023.05.003.He CC, Xiao ZY.Comprehensive treatment model and strategy for advanced liver cancer[J/OL].Chin J Hepatic Surg (Electronic Edition), 2023, 12(5): 486-489.DOI: 10.3877/cma.j.issn.2095-3232.2023.05.003.
[11]
刘晓侃, 张超杰, 赵辉.肝动脉灌注化疗及其联合治疗在中晚期肝细胞癌中的应用进展[J].肝脏, 2021, 26(12): 1411-1414.DOI:10.14000/j.cnki.issn.1008-1704.2021.12.031.Liu XK, Zhang CJ, Zhao H.Application progress of hepatic arterial infusion chemotherapy and its combination therapy in advanced hepatocellular carcinoma[J].Chin Hepatol, 2021, 26(12): 1411-1414.DOI: 10.14000/j.cnki.issn.1008-1704.2021.12.031.
[12]
He MK, Le Y, Li QJ, et al.Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J].Chin J Cancer, 2017, 36(1): 83.DOI: 10.1186/s40880-017-0251-2.
[13]
Zhao Y, Zhang YN, Wang KT, et al.Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy[J].Biochim Biophys Acta Rev Cancer, 2020, 1874(1): 188391.DOI:10.1016/j.bbcan.2020.188391.
[14]
Li Q, Han J, Yang Y, et al.PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy[J].Front Immunol,2022, 13: 1070961.DOI: 10.3389/fimmu.2022.1070961.
[15]
He M, Li Q, Zou R, et al.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J].JAMA Oncol, 2019, 5(7): 953-960.DOI: 10.1001/jamaoncol.2019.0250.
[16]
Long F, Chen S, Li R, et al.Efficacy and safety of HAIC alone vs.HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma[J].Med Oncol, 2023, 40(5): 147.DOI: 10.1007/s12032-023-02012-x.
[17]
于海东, 郭应兴, 雷振武, 等.肝动脉灌注化疗联合仑伐替尼治疗巴塞罗那临床肝癌B或C期肝细胞癌[J].中国介入影像与治疗学,2024, 21(2): 70-74.DOI: 10.13929/j.issn.1672-8475.2024.02.002.Yu HD, Guo YX, Lei ZW, et al.Hepatic artery infusion chemotherapy combined with lenvatinib for treating Barcelona clinic liver cancer stage B or C hepatocellular carcinoma[J].Chin J Interv Imag Ther,2024, 21(2): 70-74.DOI: 10.13929/j.issn.1672-8475.2024.02.002.
[18]
Lai Z, He M, Bu X, et al.Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial[J].Eur J Cancer, 2022, 174: 68-77.DOI: 10.1016/j.ejca.2022.07.005.
[19]
He MK, Liang RB, Zhao Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J].Ther Adv Med Oncol, 2021, 13:17588359211002720.DOI: 10.1177/17588359211002720.
[20]
Mei J, Tang YH, Wei W, et al.Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma[J].Front Oncol,2021, 11: 618206.DOI: 10.3389/fonc.2021.618206.
[21]
Zhu H, Shan Y, Ge K, et al.Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy[J].Cell Oncol, 2020, 43(6): 1203-1214.DOI: 10.1007/s13402-020-00552-2.
[22]
Liu WM, Fowler DW, Smith P, et al.Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses[J].Br J Cancer, 2010, 102(1):115-123.DOI: 10.1038/sj.bjc.6605465.
[23]
Mei J, Li SH, Li QJ, et al.Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma[J].J Hepatocell Carcinoma, 2021, 8: 167-176.DOI: 10.2147/JHC.S298538.
[24]
Deng H, Kan A, Lyu N, et al.Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma[J].Liver Cancer,2020, 9(3): 338-357.DOI: 10.1159/000505695.
[1] 汤宏涛, 何坤. 中晚期肝细胞癌介入治疗的进展及前景[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 305-308.
[2] 江博文, 舒畅, 赵向阳, 陶涛, 谈燚. 外周血中性粒细胞-淋巴细胞比值、血小板-淋巴细胞比值对不可切除肝细胞癌经导管动脉化疗栓塞和靶向免疫治疗疗效及预后的预测价值[J/OL]. 中华普通外科学文献(电子版), 2024, 18(02): 99-105.
[3] 赵敬柱, 郑向前, 高明, 池嘉栋, 运新伟, 李大鹏, 阮先辉. 散发性甲状腺髓样癌原发灶的切除范围及预后分析[J/OL]. 中华普通外科学文献(电子版), 2021, 15(06): 429-431.
[4] 吴春霖, 侯一夫, 陈凯, 赵冀, 唐世杰, 杨洪吉. 肝动脉灌注化疗联合PD-1/TKI 治疗不可切除性肝癌的安全性和疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 217-224.
[5] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[6] 杨秀君, 崔梦莹, 张丹, 曲仙智, 苗云皓, 盛基尧, 郑戈, 刘水, 张学文. 信迪利单抗联合仑伐替尼成功转化治疗不可切除肝癌一例[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 581-584.
[7] 李斌奎. 不可切除肝内胆管细胞癌的转化治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 511-516.
[8] 杨宇光, 唐辉, 谭志明, 麦聪, 陈铁军, 唐云强. 仑伐替尼、PD-1抑制剂联合肝动脉栓塞灌注化疗治疗不可切除肝癌疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(01): 55-60.
[9] 葛雪梅. SOX与mFOLFOX6化疗方案对晚期胃癌的疗效与安全性[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(01): 67-71.
[10] 李铜强, 石钦, 熊斌. 肝细胞癌动脉内治疗的研究进展[J/OL]. 中华介入放射学电子杂志, 2022, 10(03): 283-295.
[11] 傅云霞, 徐梓宁, 黄敬君, 郭永建, 黄文薮, 朱康顺. DEB-TACE联合仑伐替尼治疗晚期肝细胞癌的疗效和安全性[J/OL]. 中华介入放射学电子杂志, 2021, 09(02): 127-134.
阅读次数
全文


摘要